Table 4 Association of SREBP-2 haplotypes between the AVN patients and controls
Haplotype | Genotype | Controls (%) | Patients (%) | Codominant | Dominant | Recessive | |||
|---|---|---|---|---|---|---|---|---|---|
OR (95% CI) | P* | OR (95% CI) | P* | OR (95% CI) | P* | ||||
ht1 | ht1/ht1 | 51 (19.03) | 73 (16.67) | 0.78 (0.624–0.975) | 0.029 | 0.672 (0.481–0.94) | 0.020 | 0.799 (0.536–1.192) | 0.272 |
(G-G) | ht1/- | 143 (53.36) | 209 (47.72) | ||||||
-/- | 74 (27.61) | 156 (35.62) | |||||||
ht2 | h2/ht2 | 15 (5.6) | 53 (12.1) | 1.245 (0.981–1.581) | 0.071 | 1.128 (0.83–1.534) | 0.440 | 2.238 (1.231–4.069) | 0.008 |
(G-A) | ht2/- | 122 (45.52) 131 (48.88) | 184 (42.01) 201 (45.89) | ||||||
ht3 | ht3/ht3 | 16 (5.97) | 31 (7.08) | 1.081 (0.842–1.388) | 0.542 | 1.068 (0.783–1.456) | 0.678 | 1.245 (0.663–2.336) | 0.495 |
(T-G) | ht3/- | 105 (39.18) | 168 (38.36) | ||||||
-/- | 147 (54.85) | 239 (54.57) |